Trial’s Long-Term Follow-Up Data Shows No Difference in Overall Survival Among Ovarian Cancer Patients Who Did and Did Not Receive Parp Inhibitor Maintenance Therapy
Society of Gynecologic OncologyAfter resolving missing data burdens, the ENGOT-OV16/NOVA (NCT01847274) study data shows no difference in overall survival for platinum-sensitive recurrent ovarian cancer (PSROC) patients who received PARP inhibitor niraparib maintenance therapy (MT) and those who did not. Results from the trial were presented today at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer by Ursula Matulonis, MD, of the Dana-Farber Cancer Institute.